Cited by 1,117Cancer Genomics and DiagnosticsLung Cancer Treatments and MutationsChromatin Remodeling and Cancer

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

Open access

de Bruin, Elza C., McGranahan, Nicholas, Mitter, Richard, Salm, Max, Wedge, David C., Yates, Lucy, Jamal-Hanjani, Mariam, Shafi, Seema, Murugaesu, Nirupa, Rowan, Andrew J., Grönroos, Eva, Muhammad, Madiha A., Horswell, Stuart, Gerlinger, Marco, Varela, Ignacio, Jones, David, Marshall, John, Voet, Thierry, Van Loo, Peter, Rassl, Doris M., Rintoul, Robert C., Janes, Sam M., Lee, Siow-Ming, Forster, Martin, Ahmad, Tanya, Lawrence, David, Falzon, Mary, Capitanio, Arrigo, Harkins, Timothy T., Lee, Clarence C., Tom, Warren, Teefe, Enock, Chen, Shann-Ching, Begum, Sharmin, Rabinowitz, Adam, Phillimore, Benjamin, Spencer-Dene, Bradley, Stamp, Gordon, Szallasi, Zoltan, Matthews, Nik, Stewart, Aengus, Campbell, Peter, Swanton, Charles·2014·Science

DOI 10.1126/science.1253462

Open this paper in CoChat — free account

Abstract

Spatial and temporal dissection of the genomic changes occurring during the evolution of human non–small cell lung cancer (NSCLC) may help elucidate the basis for its dismal prognosis. We sequenced 25 spatially distinct regions from seven operable NSCLCs and found evidence of branched evolution, with driver mutations arising before and after subclonal diversification. There was pronounced intratumor heterogeneity in copy number alterations, translocations, and mutations associated with APOBEC cytidine deaminase activity. Despite maintained carcinogen exposure, tumors from smokers showed a relative decrease in smoking-related mutations over time, accompanied by an increase in APOBEC-associated mutations. In tumors from former smokers, genome-doubling occurred within a smoking-signature context before subclonal diversification, which suggested that a long period of tumor latency had preceded clinical detection. The regionally separated driver mutations, coupled with the relentless and heterogeneous nature of the genome instability processes, are likely to confound treatment success in NSCLC.

Integrity signals

Registry

Crossref · 10.1126/science.1253462

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Estimating the Dimension of a Model
Schwarz, G. (1978) · The Annals of Statistics · doi:10.1214/aos/1176344136 · Cited by 47,033
MEGA5: Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods
Tamura, K., Peterson, D., Peterson, N., Stecher, G., Nei, M., & Kumar, S. (2011) · Molecular Biology and Evolution · doi:10.1093/molbev/msr121 · Cited by 40,207
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,724
Cancer statistics, 2013
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Circos: An information aesthetic for comparative genomicsPreprint
Krzywinski, M. I., Schein, J. E., Birol, İ., Connors, J. M., Gascoyne, R. D., Horsman, D. E., Jones, S. J. M., & Marra, M. A. (2009) · Genome Research · doi:10.1101/gr.092759.109 · Cited by 11,073
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Self-citation
<tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool
Kent, W. J. (2002) · Genome Research · doi:10.1101/gr.229202 · Cited by 8,480

Show all 62 references

Research works printed but not linked: 1

Soria J. C., Cruz C., Bahleda R., Delord J. P., Horn L., Herbst R. S., Spigel D., Mokatrin A., Fine G., Gettinger S., Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC). Eur. J. Cancer 49 (suppl. 2), 3408 (2013).

Sorted by citations

Items 801–900 of 1,000

Molecular profile of liquid biopsies: next generation biomarkers to improve lung cancer treatment
Bianchi, F. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.598 · Cited by 5
A novel classification method for NSCLC based on the background interaction network and the edge-perturbation matrix
Tian, Y., Zhang, W., Ma, W., Huang, A., Tian, M., Zhao, J., Dang, Q., & Sun, Y. (2022) · Aging · doi:10.18632/aging.204004 · Cited by 5
Prediction of the immunological and prognostic value of five signatures related to fatty acid metabolism in patients with cervical cancer
Zeng, Q., Jiang, H., Lü, F., Fu, M., Bi, Y., Zhou, Z., Cheng, J., & Qin, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1003222 · Cited by 5
Elucidating the role of EPPK1 in lung adenocarcinoma development
Arimura, K., Kammer, M. N., Rahman, S. M. J., Chen, S., Zhao, S., Chen, H., Eisenberg, R., Zou, Y., Antic, S., Richmond, B. W., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12185-x · Cited by 5
Self-citation
Clonal ancestry in lung cancer
Alderton, G. K. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3867 · Cited by 5
Heterogeneity Among Liver Cancer—A Hurdle to Optimizing Therapy
Birkbak, N. J., & Andersen, J. B. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.063 · Cited by 5
Quantification of multiple tumor clones using gene array and sequencing data
Cheng, Y., Dai, J. Y., Paulson, T. G., Wang, X., Li, X., Reid, B. J., & Kooperberg, C. L. (2017) · The Annals of Applied Statistics · doi:10.1214/17-aoas1026 · Cited by 5
Proteomic investigation of intra-tumor heterogeneity using network-based contextualization — A case study on prostate cancer
Goh, W. W. B., Zhao, Y., Sue, A. C. ‐., Guo, T., & Wong, L. (2019) · Journal of Proteomics · doi:10.1016/j.jprot.2019.103446 · Cited by 5
Precision medicine at the academic-industry interface
Silva, P. J., & Ramos, K. S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819178-1.00053-8 · Cited by 5
Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients
Zheng, J., Zhu, Y., Sun, K., Shen, Q., Wang, Y., Cao, H., Lizaso, A., Yu, B., Lin, J., Chen, S., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.05.026 · Cited by 5
Self-citation
Molecular features of tumor-derived genetic alterations in circulating cell-free DNA in virtue of autopsy analysis
Koba, H., Kimura, H., Yoneda, T., Sone, T., Ohkura, N., Hara, J., Hosomichi, K., Tajima, A., & Kasahara, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-87094-1 · Cited by 5
Genomic evolutionary trajectory of metastatic squamous cell carcinoma of the lung
Krause, A., Roma, L., Lorber, T., Dietsche, T., Perrina, V., Müller, D. C., Lardinois, D., Ruiz, C. F., Prince, S. S., Piscuoglio, S., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-48 · Cited by 5
Cell Free Methylated Tumor DNA in Bronchial Lavage as an Additional Tool for Diagnosing Lung Cancer—A Systematic Review
Wen, S. W. C., Wen, J., Hansen, T. F., Jakobsen, A. K. M., & Hilberg, O. (2022) · Cancers · doi:10.3390/cancers14092254 · Cited by 5
Bone metastasis from lung cancer identified by genetic profiling
Liu, Z., Wang, C., Chen, H., Li, X., Dai, L., & Ding, Z. (2016) · Oncology Letters · doi:10.3892/ol.2016.5458 · Cited by 5
In Vitro Three-Dimensional Cell Cultures as Tool for Precision Medicine
Silvestri, A., Schumacher, D., Silvestrov, M., Schäfer, R., Reinhard, C., Hoffmann, J., Boehnke, K., & Regenbrecht, C. R. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-53661-3_14 · Cited by 5
Clinically significant sub-clonality for common drivers can be detected in 26% of KRAS/EGFR mutated lung adenocarcinomas
Simon, E., Bick, T., Sarji, S., Shentzer, T., Prinz, E., Yehiam, L., Sabo, E., Ben‐Izhak, O., & Hershkovitz, D. (2017) · Oncotarget · doi:10.18632/oncotarget.17399 · Cited by 5
Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET…
Scagliotti, G. V., & Maïo, M. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv334 · Cited by 5
Cancer evolution simulation identifies possible principles underlying intratumor heterogeneityPreprint
Niida, A., Ito, S., Tremmel, G., Imoto, S., Uchi, R., Takahashi, Y., Mimori, K., & Miyano, S. (2015) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/022806 · Cited by 5
Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer
Hosseini, N., Mannan, R., Rebernick, R. J., Su, F., Wang, R., Cao, X., Lako, A., Mellacheruvu, D., Hu, J., Alumkal, J. J., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-3687 · Cited by 5
Cancer in 4D: toward Spatiotemporal Hallmark Ecosystems
Sibai, M., Zacharias, M., McGranahan, N., Jamal‐Hanjani, M., & Porta‐Pardo, E. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.01.004 · Cited by 5
Self-citation
A Case-control Study Supporting the Use of Liquid Biopsy in the Targeted Therapy for Lung Cancer
Dai, L., Wang, C., & Ding, Z. (2018) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2018.19.7.1761 · Cited by 4
Precision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC
Nousias, O., Mandell, J. D., Anderson, K. S., & Townsend, J. P. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108487 · Cited by 4
Depletion-dependent activity-based protein profiling using SWATH/DIA-MS detects serine hydrolase lipid remodeling in lung adenocarcinoma progression
Sajic, T., Vizovišek, M., Arni, S., Ciuffa, R., Mehnert, M., Lenglet, S., Weder, W., Gallart‐Ayala, H., Ivanišević, J., Buljan, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59564-x · Cited by 4
Genetic and epigenetic determinants of B-cell lymphoma evolution
Izzo, F., & Landau, D. A. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000258 · Cited by 5
Single-Cell Omics: Deciphering Tumor Clonal Architecture
Dzobo, K., Thomford, N. E., Rowe, A., Senthebane, D. A., & Dandara, C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814919-5.00005-1 · Cited by 4
Core needle biopsy for screening detected lung cancer—does it capture all in light of tumor heterogeneity?—a narrative review
Binder, C., Oberndorfer, F., & Müllauer, L. (2021) · Shanghai Chest · doi:10.21037/shc-21-1 · Cited by 4
18F-Fluorodeoxyglucose PET/CT for Early Prediction of Outcomes in Patients with Advanced Lung Adenocarcinomas and EGFR Mutations Treated with First-Line EGFR-TKIs
Huang, Y.-E., Tsai, Y.-H., Huang, Y.-J., Lung, J., Ho, K.-W., Yen, T., Chan, S.-C., Chen, S.-T., Tsai, M., & Hung, M.-S. (2022) · Cancers · doi:10.3390/cancers14061507 · Cited by 6
Self-citation
Miniplatforms for Screening Biological Samples for KRAS and Four Mismatch Repair Proteins as New Tools for Fast Screening for Gastric and Colon Cancers
Staden, R. S., Bratei, A. A., Ilie‐Mihai, R., Gheorghe, D., Tuchiu-Stanca, B.-M., & Gurzu, S. (2023) · Journal of The Electrochemical Society · doi:10.1149/1945-7111/acd358 · Cited by 4
Combination of Chemical and Physical Cancer Therapeutics Developed with Microcapsules Made of κ-Casein and Gold Nanoparticles in the Presence of Drug-Loaded Phase Change Materials
Ha, Y., An, S., & Paik, S. R. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c02185 · Cited by 4
Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study
Yang, Z., Li, J., Hu, Y., Chen, M., Peng, D., Zong, D., Shang, Q., Tao, L., Zhao, Y., Ni, Y., et al. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00682-0 · Cited by 4
[Advances on Recognizing and Managing Tumor Heterogeneity].
Zhong, R., Li, H., Zhang, S., Liu, J., & Cheng, Y. (2018) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2018.09.11 · Cited by 4
Identification of Novel Multi‐Omics Expression Landscapes and Meta‐Analysis of Landscape‐Based Competitive Endogenous RNA Networks in ALDH+ Lung Adenocarcinoma Stem Cells
Yang, W. C., Liang, Y., Zheng, Y., Luo, H., Yang, X., & Li, F. (2022) · BioMed Research International · doi:10.1155/2022/9545609 · Cited by 4
Mutation divergence over space in tumour expansion
Li, H., Yang, Z., Tu, F., Deng, L., Han, Y., Fu, X., Wang, L., Gu, D., Werner, B., & Huang, W. (2023) · Journal of The Royal Society Interface · doi:10.1098/rsif.2023.0542 · Cited by 3
Pathology, Biomarkers, and Molecular Diagnostics
Franklin, W. A., Aisner, D. L., Davies, K. D., Crooks, K., Post, M. D., Kleinschmidt-DeMasters, B. K., Ashwood, E. R., Bunn, P. A., & Varella‐Garcia, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00015-3 · Cited by 4
Expression profile of CADM1 and CADM4 in triple negative breast cancer with primary systemic therapy
Kanke, Y., Saito, M., Abe, N., Saito, K., Goto, A., Ohtake, T., Murakami, Y., & Kono, K. (2018) · Oncology Letters · doi:10.3892/ol.2018.9727 · Cited by 4
Short-range migration can alter evolutionary dynamics in solid tumors
Azimzade, Y., & Saberi, A. A. (2019) · Journal of Statistical Mechanics Theory and Experiment · doi:10.1088/1742-5468/ab4983 · Cited by 4
Circulating Tumour Cells in Lung Cancer
Chemi, F., Mohan, S., & Brady, G. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-26439-0_6 · Cited by 4
Evolution tumour models paving the way for understanding oral carcinogenesis
Martins‐Chaves, R. R., Silva, R. S. O., Pereira, T. D. S. F., Fonseca, F. P., & Gomez, R. S. (2023) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.13402 · Cited by 4
Mechanisms of esophageal adenocarcinoma formation and approaches to chemopreventive intervention
Richmond, E. S., & Umar, A. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.12.001 · Cited by 4
Genomics of lung cancer
Fong, K. M., Bowman, R., & Yang, I. A. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.02.29 · Cited by 4
Detection and Characterization of Circulating Tumour Cells in Multiple Myeloma
Zhang, L., Beasley, S., Prigozhina, N. L., Higgins, R., Ikeda, S., Lee, F. Y., Marrinucci, D. C., & Jia, S. (2016) · Journal of Circulating Biomarkers · doi:10.33393/jcb.2016.2078 · Cited by 4
Circulating tumour DNA and resistance mechanisms during EGFR inhibitor therapy in lung cancer
Escriu, C., & Field, J. K. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.07.96 · Cited by 4
Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic HeterogeneityPreprint
Shi, W., Ng, C. K. Y., Lim, R. S., Jiang, T., Kumar, S., Li, X., Wali, V. B., Piscuoglio, S., Gerstein, M., Chagpar, A. B., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3155634 · Cited by 4
Statistical Mechanical theory for spatio-temporal evolution of Intra-tumor heterogeneity in cancers: Analysis of Multiregion sequencing dataPreprint
Sinha, S., Li, X., & Thirumalai, D. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.19.481164 · Cited by 4
Lung Cancer
Jamal‐Hanjani, M., & Lee, S. M. (2015) · Lung Cancer Management · doi:10.2217/lmt.15.11 · Cited by 3
Self-citation
Immunogenic cell death genes in single-cell and transcriptome analyses perspectives from a prognostic model of cervical cancer
Li, N., Xiu, L., Xu, Y., Si, Y., Zhao, H., & Ren, Q. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1532523 · Cited by 3
The prognostic value of intra- and peritumoral habitat analysis in nasopharyngeal carcinoma: combining IVIM and ASL
Yang, F., Wei, H., Wang, S., Li, X., Yu, X., Li, L., Zhao, Y., Jiang, Y., Xie, L., Lin, M., et al. (2025) · European Radiology · doi:10.1007/s00330-025-12121-y · Cited by 3
Tumor microenvironment heterogeneity and immunotherapy resistance: multidimensional modulation strategies for precision breakthroughs
Wei, Y., Li, R., Xiang, Y., Tong, H., Zhang, Y., Kang, Q., Huang, J., Bao, Y., & Ma, X. (2026) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.12.004 · Cited by 3
Cancer Prevention Clinical Trials: Advances and Challenges
Francis, E. R., Syed, D. F., Rajan, A., & Szabo, E. M. (2026) · Cancers · doi:10.3390/cancers18030390 · Cited by 3
Combination Approaches in NSCLC Involving Immune Checkpoint Inhibitors
Arulananda, S., Rivalland, G., & John, T. (2016) · Lung Cancer Management · doi:10.2217/lmt-2016-0013 · Cited by 3
scGAL: unmask tumor clonal substructure by jointly analyzing independent single-cell copy number and scRNA-seq data
Li, R., Shi, F., Song, L., & Yu, Z. (2024) · BMC Genomics · doi:10.1186/s12864-024-10319-w · Cited by 3
Somatic genome alterations in relation to age in lung squamous cell carcinoma
Meucci, S., Keilholz, U., Heim, D., Klauschen, F., & Cacciatore, S. (2018) · Oncotarget · doi:10.18632/oncotarget.25848 · Cited by 3
Metachronous primary lung adenocarcinomas harboring distinct KRAS mutations
Hu, Y. W., Ren, S., Chen, C., Liang, Q., Yu, F., & Liu, W. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13458 · Cited by 3
Revealing the subtyping of non‐small cell lung cancer based on genomic evolutionary patterns by multi‐region sequencing
Liao, G., Liang, X., Ping, Y., Zhang, Y., Liao, J., Wang, Y., Hou, X., Jiang, Z., Dong, X., Xu, C., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3541 · Cited by 3
Unique evolutionary trajectories of breast cancers with distinct genomic and spatial heterogeneity
Phung, T. N., Webster, T. H., Lenkiewicz, E., Malasi, S., Andreozzi, M., McCullough, A. E., Anderson, K. S., Pockaj, B. A., Wilson, M. A., & Barrett, M. T. (2021) · Scientific Reports · doi:10.1038/s41598-021-90170-1 · Cited by 3
The role of single-cell sequencing in studying tumour evolution
Mossner, M., Baker, A., & Graham, T. A. (2021) · Faculty Reviews · doi:10.12703/r/10-49 · Cited by 5
Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas
Fujino, T., Suda, K., Sakai, K., Murakami, I., Shimizu, S., Ohara, S., Koga, T., Hamada, A., Soh, J., Nishio, K., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.09.005 · Cited by 3
Mitochondrial cristae: lung cancer metabolism architects
Noguchi, M., & Scorrano, L. (2023) · Life Metabolism · doi:10.1093/lifemeta/load015 · Cited by 3
Improving cellular phylogenies through the integrated use of mutation order and optimality principles
Miura, S., Dolker, T., Sanderford, M. D., & Kumar, S. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.07.018 · Cited by 3
Identification of hypoxia‐related gene signatures based on multi‐omics analysis in lung adenocarcinoma
Luo, Q., Li, X., Meng, Z., Rong, H., Li, Y., Zhao, G., Zhu, H., Cen, L., & Liao, Q. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18032 · Cited by 2
Neural Network Deconvolution Method for Resolving Pathway-Level Progression of Tumor Clonal Expression Programs With Application to Breast Cancer Brain Metastases
Tao, Y., Lei, H., Lee, A. V., Ma, J., & Schwartz, R. S. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.01055 · Cited by 3
Intratumor Heterogeneity and Transcriptional Profiling in Glioblastoma: Translational Opportunities
Piccirillo, S. G. M., & Spiteri, I. (2015) · Future Neurology · doi:10.2217/fnl.15.16 · Cited by 3
Penalized integrative semiparametric interaction analysis for multiple genetic datasets
Li, Y., Li, R., Lin, C., Qin, Y., & Ma, S. (2019) · Statistics in Medicine · doi:10.1002/sim.8172 · Cited by 3
Phylogenies Derived from Matched Transcriptome Reveal the Evolution of Cell Populations and Temporal Order of Perturbed Pathways in Breast Cancer Brain Metastases
Tao, Y., Lei, H., Lee, A. V., Ma, J., & Schwartz, R. S. (2019) · Lecture notes in computer science · doi:10.1007/978-3-030-35210-3_1 · Cited by 3
Characterizing Intra-Tumor Heterogeneity From Somatic Mutations Without Copy-Neutral Assumption
Ogundijo, O., Zhu, K., Wang, X., & Anastassiou, D. (2020) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2020.2973635 · Cited by 3
Molecular pathology
Laenger, F., Dickgreber, N. J., & Lehmann, U. (2015) · European Respiratory Society eBooks · doi:10.1183/2312508x.10009814 · Cited by 3
Genomic Alteration Spectrum of Non-Small Cell Lung Cancer Patients in East-China Characterized by Tumor Tissue DNA and Cell-Free DNA
Li, J., Chen, S., Xue, H., Wang, H., Huang, T., Xie, H., He, J., Cai, K., Yu, Z., & Ni, B. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s351085 · Cited by 3
Self-citation
Towards a Molecular Classification of Pulmonary Sarcomatoid Carcinomas
Mansfield, A. S., Roden, A. C., & Boland, J. M. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.012 · Cited by 3
TRAC(ERx)-ing lung cancer evolution
Devarakonda, S. H. K., & Govindan, R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx313 · Cited by 3
Spatial Transcriptomics Inferred from Pathology Whole-Slide Images Links Tumor Heterogeneity to Survival in Breast and Lung CancerPreprint
Levy-Jurgenson, A., Tekpli, X., Kristensen, V. N., & Yakhini, Z. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.02.183814 · Cited by 4
AtlasXbrowser enables spatial multi-omics data analysis through the precise determination of the region of interestPreprint
Barnett, J., Silverman, J., Wetzel, M., Rao, P., Sotudeh, N., & Wang, L. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.11.491526 · Cited by 3
The cytidine deaminase APOBEC3G drives cancer mutagenesis and clonal evolution in bladder cancerPreprint
Liu, W., Newhall, K. P., Khani, F., Barlow, L. J., Nguyen, D. D., Gu, L. C., Eng, K. W., Bhinder, B., Uppal, M., Récapet, C., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.05.503899 · Cited by 3
Subclonal mutation load predicts survival and response to immunotherapy in cancers with low to moderate tumor mutation burdenPreprint
Jiang, Y., Montierth, M. D., Yu, K., Ji, S., Tran, Q., Liu, X., Lal, J. C., Guo, S., Wu, A., Dai, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.03.601939 · Cited by 3
Systematic investigation of the prognostic impact of clonal status of somatic mutations across multiple cancer types
Cheng, P., Lan, Y., Liao, J., Zhao, E., Yan, H., Xu, L., Suru, A., Ping, Y., & Xu, J. (2022) · Genomics · doi:10.1016/j.ygeno.2022.110412 · Cited by 2
Identification of the differences in molecular networks between idiopathic pulmonary fibrosis and lung squamous cell carcinoma using machine learning
Nojima, Y., & Mizuguchi, K. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108560 · Cited by 2
Genomic Instability is Widespread in Esophageal Squamous Dysplasia and Increases During the Progression to Cancer
An, H., Cheng, X. F., Xue, L., Wang, G., Zhu, X., Li, J., Xiao, T., & Cheng, S. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl41107 · Cited by 2
Serial Functional and Genomic Analyses Illuminate Clonal Evolution in Metastatic NSCLC with 12-Year Survival
Bakaya, V. S., Schneider, S. A., Nguyen, T., Phu, D. C., Alvarez, L. A., Evans, S. S., Bernard, P. J., Francisco, F. R., Nagourney, A. J., Torres, L., et al. (2025) · Current Oncology · doi:10.3390/curroncol32110646 · Cited by 2
Tobacco Smoking and Lung Cancer Risk After Negative Baseline Low-Dose Computed Tomography Findings
Liu, Y., Guo, X., Qie, R., Chen, Q., Xu, H., Wang, X., Liu, H., Wang, H., Kang, R., Zhao, M., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.1913 · Cited by 2
Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets
Zhang, K.-Y., Zhu, X.-Z., Yan, Y., Ying, X.-H., Zhang, J., & Wang, Z. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02850-x · Cited by 3
Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma
Craig, A. J., Labgaa, I., Villacorta-Martín, C., Ningarhari, M., & Villanueva, A. (2017) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-56197-4_1 · Cited by 2
Tumor Heterogeneity and Testing Discrepancy Confound ROS1 Detection in NSCLC
Sun, T. Y., Stehr, H., Suarez, C. J., & Wakelee, H. A. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.011 · Cited by 2
Pediatric Sarcomas: The Next Generation of Molecular Studies
Giannikopoulos, P., & Parham, D. M. (2022) · Cancers · doi:10.3390/cancers14102515 · Cited by 4
Understanding Head and Neck Cancer Evolution to Guide Therapeutic Approaches
O’Leary, B. (2023) · Springer eBooks · doi:10.1007/978-3-031-23175-9_6 · Cited by 2
Heterogeneous distribution of EGFR mutation in NSCLC: Case report
Boukansa, S., Benbrahim, Z., Gamrani, S., Mouhrach, I., Agy, F. E., Bardai, S. E., Bouguenouch, L., Serraj, M., Amara, B., Ouadnouni, Y., et al. (2023) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2023.101871 · Cited by 2
Heterogenous profiles between primary lung cancers and paired brain metastases reveal tumor evolution
Chen, Y., Dai, X., Wang, J., Tao, C., Wang, Y., Zhu, Q., Wang, Z., Zhang, T., Lan, Q., & Zhao, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1026099 · Cited by 2
The COMPASS complex maintains the metastatic capacity imparted by a subpopulation of cells in UPS
Ban, G. I., Puviindran, V., Yu, X., Nadesan, P., Tang, Y. J., Ou, J., Guardino, N. J., Nakagawa, M., Browne, M. R., Wallace, A., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110187 · Cited by 2
Implementing distinct spatial proteogenomic technologies: opportunities, challenges, and key considerations
Verstappe, B., & Scott, C. L. (2024) · Clinical & Experimental Immunology · doi:10.1093/cei/uxae077 · Cited by 3
Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma
Torasawa, M., Yoshida, T., Shiraishi, K., Yagishita, S., Ono, H., Uehara, Y., Miyakoshi, J., Tateishi, A., Igawa, Y. S., Higashiyama, R. I., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108494 · Cited by 2
Bayesian nonparametric clustering with feature selection for spatially resolved transcriptomics data
Zhu, B., Hu, G., Xu, L., Fan, X., & Li, Q. (2025) · The Annals of Applied Statistics · doi:10.1214/25-aoas2014 · Cited by 2
Hétérogénéité des tumeurs : l’apport du séquençage sur cellules individuelles
Jordan, B. (2014) · médecine/sciences · doi:10.1051/medsci/20143012023 · Cited by 3
Computational Approaches to Accelerating Novel Medicine and Better Patient Care from Bedside to Benchtop
Sakellaropoulos, T., Hur, J., Melas, I. N., Guo, E. Y., Alexopoulos, L. G., Bohlooly, M., & Bai, J. P. F. (2015) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2015.09.005 · Cited by 2
Impact of genomic sequencing on precision medicine for clinical oncology
Araujo, L. H., Krook, M. A., & Roychowdhury, S. (2016) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2016.1184966 · Cited by 2
Personalized Medicine Through Advanced Genomics
Youngblood, M. W., Erson-Omay, Z., & Günel, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-49864-5_3 · Cited by 2
Clinical research in small genomically stratified patient populations
Martín-Liberal, J., & Rodon, J. A. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.008 · Cited by 2
Cancer Clonal Evolution and Intra-tumor Heterogeneity
Fanale, D., Iovanna, J., Giordano, A., Rolfo, C. D., & Russo, A. D. (2017) · Current clinical pathology · doi:10.1007/978-3-319-55661-1_3 · Cited by 2
Evolution and cancer medicine — transformative insights
Symposium, A. M., Sahai, E. A., & Swanton, C. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.121 · Cited by 2
Self-citation
Intratumoral heterogeneity and biomarkers for transformation into small cell lung carcinomas from lung adenocarcinomas
Lee, H. J., & Um, S. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.10.91 · Cited by 2
The next generation personalized models to screen hidden layers of breast cancer tumorigenicity
Afzali, F., Akbari, P., Naderi‐Manesh, H., & Gardaneh, M. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05159-2 · Cited by 2
Cancer Genomics
Mardis, E. R. (2015) · F1000Research · doi:10.12688/f1000research.6645.1 · Cited by 2
RNA Editors and DNA Mutators: Cancer Heterogeneity Through Sequence Diversification
Tasakis, R. N., Papavasiliou, F. N., & Shaknovich, R. (2019) · OBM Genetics · doi:10.21926/obm.genet.1902072 · Cited by 2

Authors: de Bruin, E. C., McGranahan, N., Mitter, R., Salm, M., Wedge, D. C., Yates, L., Jamal-Hanjani, M., Shafi, S., Murugaesu, N., Rowan, A. J., Grönroos, E., Muhammad, M. A., Horswell, S., Gerlinger, M., Varela, I., Jones, D., Marshall, J., Voet, T., Van Loo, P., Rassl, D. M., Rintoul, R. C., Janes, S. M., Lee, S.-M., Forster, M., Ahmad, T., Lawrence, D., Falzon, M., Capitanio, A., Harkins, T. T., Lee, C. C., Tom, W., Teefe, E., Chen, S.-C., Begum, S., Rabinowitz, A., Phillimore, B., Spencer-Dene, B., Stamp, G., Szallasi, Z., Matthews, N., Stewart, A., Campbell, P., & Swanton, C.
Affiliations: Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London WC1E 6BT, UK.
Cancer Research UK (GB)
Wellcome Sanger Institute (GB)
University of Cambridge (GB)
Cancer Research UK London Research Institute, London WC2A 3LY, UK.
Universidad de Cantabria (ES)
Wellcome Trust Sanger Institute, Hinxton, CB10 1SA, UK.
Papworth Hospital NHS Foundation Trust (GB)
University College London (GB)
Thermo Fisher Scientific (United States) (US)
Technical University of Denmark, 2800 Kongens Lyngby, Denmark.
Corresponding author: McGranahan, Nicholas
Mitter, Richard
Salm, Max
Wedge, David C.
Yates, Lucy
Swanton, Charles
ORCID: McGranahan, Nicholas
Mitter, Richard
Salm, Max
Wedge, David C.
Yates, Lucy
Murugaesu, Nirupa
Rowan, Andrew J.
Horswell, Stuart
Gerlinger, Marco
Varela, Ignacio
Jones, David
Voet, Thierry
Rassl, Doris M.
Rintoul, Robert C.
Janes, Sam M.
Lee, Siow-Ming
Forster, Martin
Lawrence, David
Falzon, Mary
Capitanio, Arrigo
Harkins, Timothy T.
Lee, Clarence C.
Teefe, Enock
Begum, Sharmin
Rabinowitz, Adam
Stamp, Gordon
Matthews, Nik
Campbell, Peter
Swanton, Charles
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2014-10-10
Volume: 346
Issue: 6206
Pages: 251-256
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.1253462
OpenAlex: W2108371618
Cited by: 1,117
References: 62
Citations by year: 2026: 38 · 2025: 43 · 2024: 59 · 2023: 82 · 2022: 82 · 2021: 86 · 2020: 99 · 2019: 113 · 2018: 111 · 2017: 145 · 2016: 131 · 2015: 119 · 2014: 9
FWCI: 43.17
Type: journal article
Language: en
Open access: green
hdl.handle.net
Licence: other-oa
Locations: Science (publishedVersion)
PubMed (publishedVersion)
UCrea (University of Cantabria) (acceptedVersion, other-oa)
LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
UCL Discovery (University College London) (submittedVersion)
Research Explorer (The University of Manchester) (submittedVersion)
Apollo (University of Cambridge) (submittedVersion)
Apollo
Funders: Prostate Cancer Foundation
Breast Cancer Research Foundation
Wellcome Trust (091730, 105104, 088340)
Cancer Research UK (259303, A11590, A4688, A17786, 17001, A19310, 17786, 18377)
National Institute for Health and Care Research (CL-2011-18-001)
Academy of Medical Sciences (AMS-SGCL7-Murugaesu)
University College London
European Commission (259303)
Rosetrees Trust (M35-F1-CD1)
Fonds Wetenschappelijk Onderzoek
Ministerio de Economía y Competitividad
Vlaamse regering
National Institutes of Health
Medical Research Council
NIHR Cambridge Biomedical Research Centre
National Cancer Institute
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: non-small cell lung cancer, tumor evolution, intratumoral heterogeneity, driver mutations, copy number alterations, chromosomal translocation, APOBEC mutational signature, genome doubling, tumor latency, carcinogen exposure, genomic instability
MeSH terms: APOBEC-1 Deaminase, Carcinogens, Carcinoma, Non-Small-Cell Lung, Cytidine Deaminase, Humans, Lung Neoplasms, Mutation, Neoplasm Recurrence, Local, Prognosis, Smoking, Translocation, Genetic, Tumor Cells, Cultured, Gene Dosage, Genetic Heterogeneity, Evolution, Molecular, Genomic Instability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks